QV Bioelectronics Company Market Research Report

Company Overview

Name and Mission of the Company

Name: QV Bioelectronics

Mission: Delivering longer, better quality lives for brain tumour patients.

Founding Details

Founded: 2018

Founders: Dr. Chris Bullock (Biomedical Engineer) and Dr. Richard Fu (Neurosurgeon)

Key People

Dr. Chris Bullock: CEO & Co-Founder

Dr. Richard Fu: Clinical Director & Co-Founder

Sabine Ficek: CFO

Alastair Atkinson: Non-Executive Chairman

Dr. Deepak Kotak: Non-Executive Director

Joel Treen: Head of Quality

Qasim Akhtar: Head of Business Development

Dr. Nimrah Munir: Principal Scientist, Biomaterials

Dr. Ashwin Narayanan: Principal Scientist, Cancer Biology

Liz Freeman: Finance/HR Manager

Headquarters

Location: 21 LGA, Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom

Number of Employees

Employees: 11-50

Revenue

Revenue: No information is available

Company Recognition

Known For: Developing an implantable electric field therapy treatment for aggressive brain tumours, specifically focusing on Glioblastoma.

Products

Main Product Offering

GRACE (Glioma Resection Advanced Cavity Electric field therapy):

Description: An innovative implanted device offering electric field therapy directly to tumour resection margins, designed to address Glioblastoma.

Key Features:

Delivers electric field therapy continuously through an implant.

Targets areas where 90% of GBM recurrence occurs.

Intended to improve patient quality of life with a minimally invasive approach.

Electric Field Therapy (EFT)

Description: Utilizes specific electrical frequencies to halt cancer cell cycles and slow tumour growth.

Features:

Approved for clinical efficacy in treating Glioblastoma.

Represents a novel cancer treatment approach.

Recent Developments

Advancements and New Initiatives

Pre-Clinical Results: Achieved breakthrough pre-clinical safety and efficacy results for electric field therapy in Glioblastoma treatment.

Safety and Efficacy: Demonstrated success in large animal studies for up to three months without significant adverse events.

Innovate UK Funding: Secured £343,000 from Innovate UK’s Cancer Therapeutics program to develop treatment for childhood brain tumours.

Strategic Collaborations: Successful collaboration with Incubate Bio to progress GRACE.

New Products and Features: No new distinct product launches, but enhancements and expansion focus on childhood brain cancer.

Partnerships and Collaborations

Collaborated with Incubate Bio for strategic insights critical to advancing GRACE.

Market Position and Future Outlook

Market: Targeting a market worth over $30 billion with innovative technology aimed at disrupting current dominated spaces.

Series A Investment: Engaged in raising Series A investment to facilitate product development and extend reach in neuro-oncology.

FDA Progress: Achieved positive feedback from the FDA on validation plans, paving the way for first-in-human trials.

Milestones and Recognition

Celebrating 6 years, acknowledged major strides in developing the world’s first implantable electric field therapy for Glioblastoma.

Notable financial backing with equity funding exceeding $4M and grant funding over $3M, showcasing growth and innovation.

Contact Information

Office Address: 21 LGA, Alderley Park, Macclesfield, Cheshire, SK10 4TG

Email: info@qvbio.co.uk

Investor Contact: investorrelations@qvbio.co.uk

This report compiles the available information on QV Bioelectronics, focusing on company operations, product offerings, recent company developments, and strategic initiatives in the medical field. Given their niche in neuro-oncology and electric field therapy, QV Bioelectronics continues to make significant strides in advancing cancer treatment technology.